(Q38052452)

27 August 2017

title

Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy (English)

1 reference

27 August 2017

Sara S Roscioni

1

1 reference

27 August 2017

Dick de Zeeuw

series ordinal

2

1 reference

27 August 2017

Stephan J L Bakker

series ordinal

3

1 reference

27 August 2017

Hiddo J Lambers Heerspink

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

16 October 2012

1 reference

Nature Reviews Nephrology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

691-699

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2012.217

27 August 2017

exact match

0 references

cites work

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Mineralocorticoid receptor blockade in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Distinguishing the antihypertensive and electrolyte effects of eplerenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The frequency of hyperkalemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

A mechanism for hyporeninemic hypoaldosteronism in chronic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Hyperkalemia and hyporeninemic hypoaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Prostaglandin E2-induced aldosterone release is mediated by an EP2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Extrarenal potassium tolerance in chronic renal failure: implications for the treatment of acute hyperkalemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Diuretic use in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Potassium metabolism in patients with chronic kidney disease (CKD), Part I: patients not on dialysis (stages 3-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The utility of the transtubular potassium gradient in the evaluation of hyperkalemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone-receptor deficiency in pseudohypoaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Spironolactone diuresis in patients with cirrhosis and ascites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Urine electrolytes and osmolality: when and how to use them

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Spironolactone dose-response relationships in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The transtubular potassium concentration in patients with hypokalemia and hyperkalemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Hyperkalemia: An adaptive response in chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Diabetes and drug-associated hyperkalemia: effect of potassium monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Safety of low-dose spironolactone administration in chronic haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Calcium salts in management of hyperkalaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Hypokalaemia and hyperkalaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Electrocardiographic manifestations of hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Analysis of factors causing hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Isolated hypoaldosteronism in adults. A renin-deficiency syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Heparin-induced hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Adrenergic Modulation of Extrarenal Potassium Disposal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Blunted kaliuresis after an acute potassium load in patients with chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Relative potency of prorenoate and spironolactone in normal man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

The action of hydroflumethiazide in relation to adrenal steroids and potassium loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Trans-tubular potassium gradient in patients with drug-induced hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Variability in potassium removal by hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.217

Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone

31 March 2020

1 reference

12 December 2020

Treatment of hyperkalemia in patients with chronic kidney disease--a focus on medications.

1 reference

12 December 2020

Disorders of steroid 17 alpha-hydroxylase deficiency

1 reference

12 December 2020

Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man

1 reference

12 December 2020

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

12 December 2020

Correlation between creatinine clearance and transtubular potassium concentration gradient in old people and chronic renal disease patients.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.217

1 reference

Dimensions Publication ID

27 August 2017

1044229777

0 references

Fatcat ID

release_32d73gzstnaudilayvfi22fceu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/32d73gzstnaudilayvfi22fceu

24 November 2022

mapped directly with Wikidata item

1 reference